$4.06
4.10% day before yesterday
Nasdaq, Jun 06, 10:00 pm CET
ISIN
US47010C3007
Symbol
JAGX
Sector
Industry

Jaguar Health, Inc. Stock price

$4.06
-6.85 62.79% 1M
-19.84 83.01% 6M
-21.19 83.92% YTD
-91.19 95.74% 1Y
-165,337.19 100.00% 5Y
-2,232,562,495.94 100.00% 10Y
-2,402,662,495.94 100.00% 20Y
Nasdaq, Closing price Fri, Jun 06 2025
+0.16 4.10%
ISIN
US47010C3007
Symbol
JAGX
Sector
Industry

Key metrics

Market capitalization $5.13m
Enterprise Value $36.51m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.16
P/S ratio (TTM) P/S ratio 0.44
P/B ratio (TTM) P/B ratio 0.64
Revenue growth (TTM) Revenue growth 13.91%
Revenue (TTM) Revenue $11.55m
EBIT (operating result TTM) EBIT $-32.04m
Free Cash Flow (TTM) Free Cash Flow $-29.65m
Cash position $5.69m
EPS (TTM) EPS $-63.40
P/E forward negative
P/S forward 0.39
EV/Sales forward 2.75
Short interest 3.27%
Show more

Is Jaguar Health, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,823 stocks worldwide.

Jaguar Health, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

2 Analysts have issued a Jaguar Health, Inc. forecast:

2x Buy
100%

Analyst Opinions

2 Analysts have issued a Jaguar Health, Inc. forecast:

Buy
100%

Financial data from Jaguar Health, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
12 12
14% 14%
100%
- Direct Costs 2.04 2.04
4% 4%
18%
9.51 9.51
19% 19%
82%
- Selling and Administrative Expenses 26 26
15% 15%
222%
- Research and Development Expense 16 16
12% 12%
138%
-30 -30
0% 0%
-261%
- Depreciation and Amortization 1.88 1.88
6% 6%
16%
EBIT (Operating Income) EBIT -32 -32
1% 1%
-277%
Net Profit -40 -40
4% 4%
-344%

In millions USD.

Don't miss a Thing! We will send you all news about Jaguar Health, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Jaguar Health, Inc. Stock News

Neutral
Accesswire
2 days ago
Click here to register SAN FRANCISCO, CA / ACCESS Newswire / June 6, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that Lisa Conte, the company's founder, president and CEO, will participate in a virtual fireside chat at 9:00 AM Eastern on Tuesday, June 10, 2025, as part of Lytham Partners' spring 2025 Spotlight Series. The discussion will focus on Jaguar's ongoing efforts to further...
Neutral
Accesswire
18 days ago
SAN FRANCISCO, CA / ACCESS Newswire / May 21, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or "the Company"), today announced that it has entered into definitive agreements for the purchase and sale of 246,306 shares of common stock at a purchase price of $6.09 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company...
Neutral
Accesswire
19 days ago
As announced , initial proof-of-concept (POC) results from distinct ongoing investigator-initiated trial (IIT) in Abu Dhabi show crofelemer reduced total parenteral support in a pediatric MVID patient with intestinal failure by up to 27%; per the IIT protocol, patient was taken off crofelemer after 12 weeks of treatment for a period of 30 days, but was restarted on daily crofelemer treatment af...
More Jaguar Health, Inc. News

Company Profile

Jaguar Health, Inc. is a commercial stage pharmaceuticals company, which engages in the development of gastrointestinal products. Its products include Canalevia, Equilevia, and Neonorm. It operates through the Human Health and Animal Health segments. The Human Health segment manufactures human products and the ongoing advertising of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Animal Health segment commercializes prescription and non-prescription products for companion and production animals. The company was founded by Lisa A. Conte on June 6, 2013 and is headquartered in San Francisco, CA.

Head office United States
CEO Lisa Conte
Employees 49
Founded 2013
Website jaguar.health

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today